UNSPSC 51361907: Brallobarbital

This classification denotes a barbiturate with the molecular formula C10H11BrN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D0N7A2M3MU, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-bromo-2-propenyl)-5-(2-propenyl)- but generally known as brallobarbital, which bears US NIH Compound Identifier 68416. European Medicines Agency schedules Brallobarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05880MIG.

UNSPSC 51361907 Brallobarbital, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The three most recent opportunities solicited under this code involve naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and OTC products through a multistate cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations involve brallobarbital, a barbiturate pharmaceutical, suggesting a tagging or taxonomy mismatch between the code designation and the actual goods being procured.

The issuing bodies span county health departments, state health and human services agencies, and multistate cooperative purchasing organizations. The geographic spread includes Florida, Texas, and Minnesota with participation from Oregon through the cooperative purchasing vehicle. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023), the Texas HHS Commission's Request for Information on direct-to-manufacturer prescription programs (posted April 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026). The code shows little relevant recent activity in its stated commodity; firms evaluating this code should verify the correct UNSPSC designation for their intended pharmaceutical product line before pursuing opportunities.